BioAdvance Invests In Midway Pharmaceuticals To Support Promising Development Program For GI Therapies  
5/17/2006 12:51:53 PM

PHILADELPHIA--(BUSINESS WIRE)--May 17, 2006--BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and one of the nation's leading investors in early stage biotechnology companies, today announced that it has invested $500,000 in Midway Pharmaceuticals, a recently founded company working to develop novel non-antibiotic therapies for a range of gastrointestinal diseases (GI) including Crohn's disease and ulcerative colitis.